Caribou Biosciences shuts down after failing to fund Phase 3 lymphoma trial
The company will discontinue clinical development of its two CRISPR-based CAR-T therapies, including vispa-cel for advanced B-cell non-Hodgkin lymphoma.
The company will discontinue clinical development of its two CRISPR-based CAR-T therapies, including vispa-cel for advanced B-cell non-Hodgkin lymphoma.